Skip to content

Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies

Effects of Nucleus Basalis of Meynert Area Electrical Stimulation on Cognitive Behavioral Disorders in Dementia With Lewy Bodies : A Pilot Phase 1 Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01340001
Acronym
DEMENSTIM
Enrollment
6
Registered
2011-04-21
Start date
2012-10-24
Completion date
2017-12-22
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia With Lewy Bodies

Keywords

Dementia with Lewy bodies, Nucleus basalis of Meynert, Deep brain stimulation

Brief summary

Deep brain stimulation has been developed as a substitute for the classical lesioning methods previously used in stereotactic and functional neurosurgery. Recent, anecdotal cases reports suggested that electrical stimulation of the cholinergic output of the Nucleus Basalis of Meynert (NBM) may improve cognitive performances, especially the memory tasks. The present study aims to assess the effect of bilateral electrical stimulation of the NBM on the mnesic performance \[assessed by the sum of the three free recalls of the Free and Cued Selective Recall Reminding Test (FCSRT)\] in patients diagnosed with probable, moderate, Dementia with Lewy Bodies.

Interventions

PROCEDUREElectrical stimulation of the nucleus basalis of Meynert

Differents parameters will be assessed.

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of probable Lewy-body dementia according to the internationally accepted consensus criteria (McKeith, 2005) * Outpatients, male or female, aged between 18 to 75 years * Moderate dementia defined by a mini-mental state examination (MMSE) score between 16 and 26 * Stable dose of cholinesterase inhibitors (maximal dose tolerated) for a minimum of 1 months * Patients receiving antiparkinsonian treatment unmodified for 3 months, if treated * French as native language * Written informed consent of the patient * Written informed consent of the caregiver

Exclusion criteria

* Other causes of dementia (Alzheimer dementia, vascular dementia, dementia associated with Parkinson's disease) * Other causes of extrapyramidal symptoms (Parkinson's disease) * Patients with a history of severe psychiatric disorders, such as psychosis. Earlier episodes of depression and/or anxiety without hospitalization are not

Design outcomes

Primary

MeasureTime frameDescription
free recalls of the FCSRTbetween the assessments (Month 7) and (Month 10)The primary endpoint of the study is the difference in the sum of the three free recalls of the FCSRT between the assessments (M7) and (M10), i.e. the comparison of the performances with and without NBM electrical stimulation.

Secondary

MeasureTime frameDescription
performances on different testsdifferent tests recorded at Month 7 and Month 10Comparison will be made between the performances on different tests recorded at M7 and M10, to evaluate the effect of bilateral electrical stimulation of the NBM on cognitivo-behavioral disorders.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026